Table 3

Grade ≥3 TEAEs

Grade ≥3 TEAEs, preferred term, n (%)E7046 dose (mg)
125
(n=8)
250
(n=8)
500
(n=7)
750
(n=7)
Combined
(N=30)
Abdominal pain01 (12.5)01 (14.3)2 (6.7)
Alanine aminotransferase increased01 (12.5)001 (3.3)
Anaphylactic reaction01 (12.5)001 (3.3)
Ascites02 (25.0)002 (6.7)
Bile duct obstruction01 (12.5)001 (3.3)
Blood bilirubin increased1 (12.5)0001 (3.3)
Blood lactate dehydrogenase increased1 (12.5)0001 (3.3)
Cancer pain01 (12.5)001 (3.3)
Cardiopulmonary failure1 (12.5)0001 (3.3)
Constipation001 (14.3)01 (3.3)
Death1 (12.5)0001 (3.3)
Dizziness0001 (14.3)1 (3.3)
Duodenal stenosis01 (12.5)001 (3.3)
Dysarthria001 (14.3)01 (3.3)
Fatigue001 (14.3)01 (3.3)
Hepatic function abnormal01 (12.5)001 (3.3)
Hypernatremia001 (14.3)01 (3.3)
Hypersensitivity01 (12.5)001 (3.3)
Hypertriglyceridemia0001 (14.3)1 (3.3)
Hyperuricemia0001 (14.3)1 (3.3)
Hyponatremia001 (14.3)01 (3.3)
Hypophosphatemia01 (12.5)001 (3.3)
Large intestinal obstruction1 (12.5)0001 (3.3)
Lymphocyte count decreased01 (12.5)001 (3.3)
Myocardial infarction0001 (14.3)1 (3.3)
Nausea01 (12.5)001 (3.3)
Pleural effusion01 (12.5)001 (3.3)
Pneumonia1 (12.5)0001 (3.3)
Rash01 (12.5)001 (3.3)
Rash generalized001 (14.3)01 (3.3)
Small intestinal obstruction1 (12.5)001 (14.3)2 (6.7)
Tumor hemorrhage01 (12.5)001 (3.3)
Vomiting1 (12.5)1 (12.5)01 (14.3)3 (10.0)
  • TEAE, treatment-emergent adverse event.